ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,343Medicare Part D Prescriptions Filled, Including Refills

Rank: 317 out of 1677

$691K Total Retail Price of All Prescriptions

Rank: 184 out of 1677

630 Patients Receiving at Least One Drug in Part D
58%Patients 65 Years and Older
86% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Georgia
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

9% of this provider’s 630 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 5,989 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

32% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$67 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Georgia
LISINOPRIL 673 360 1 3
AMLODIPINE BESYLATE 552 354 2 2
HYDROCHLOROTHIAZIDE 548 340 3 9
NEXIUM 546 360 4 19
SIMVASTATIN 542 318 5 1
IBUPROFEN 362 171 6 83
CRESTOR 299 205 7 28
FUROSEMIDE 276 148 8 8
METFORMIN HCL 272 162 9 7
TRAMADOL HCL 232 136 10 16
NAPROXEN 194 111 11 87
HYDROCODONE-ACETAMINOPHEN 181 93 S3 12 4
FLUTICASONE PROPIONATE 157 63 13 29
LANTUS 145 73 14 44
LOSARTAN POTASSIUM 131 90 15 25
XOPENEX HFA 131 88 15 248
DOXAZOSIN MESYLATE 128 102 17 90
OMEPRAZOLE 128 81 17 6
COZAAR 126 89 10 19 254
LEVOTHYROXINE SODIUM 116 63 20 5
TOPROL XL 116 83 20 215
GLIMEPIRIDE 113 76 22 33
GABAPENTIN 113 55 22 11
METOPROLOL SUCCINATE 111 66 24 23
CARVEDILOL 103 66 25 20
ALLOPURINOL 102 66 26 31
ATENOLOL 98 69 27 21
POTASSIUM CHLORIDE 96 57 28 14
SYMBICORT 90 40 29 150
CLONIDINE HCL 83 51 30 36
GLIPIZIDE XL 82 54 31 123
SERTRALINE HCL 81 69 32 26
METOPROLOL TARTRATE 77 42 33 12
RANITIDINE HCL 73 35 34 18
TRIAMCINOLONE ACETONIDE 72 44 35 134
DICLOFENAC SODIUM 72 45 35 95
ACTOS 70 51 37 104
NOVOLIN 70-30 69 50 38 155
INSULIN SYRINGE 64 31 39 72
PROAIR HFA 63 33 40 50
CYCLOBENZAPRINE HCL 63 13 R 40 52
TRIAMTERENE-HCTZ 61 36 42 61
ISOSORBIDE MONONITRATE ER 56 24 43 73
FELODIPINE ER 55 43 44 193
ACETAMINOPHEN-CODEINE 55 45 S3 44 136
VENTOLIN HFA 53 11 46 89
HYDRALAZINE HCL 51 21 47 69
CLOPIDOGREL 50 18 48 32
LOSARTAN-HYDROCHLOROTHIAZIDE 50 29 48 42
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 1, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.